Reports On Company: Gujarat Themis Biosyn
| Buy Gujarat Themis Biosyn for target price of Rs 909: HDFC Securities | |
| Company: | Gujarat Themis Biosyn |
| Brokerage: | HDFC Sec |
| Date of report: | January 2, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 17% |
| Summary: | Prior to FY20, company was engaged in contract manufacturing of Rifamycin S for Lupin. During FY20, management decided to change business model from contract manufacturing to manufacturing and sales model; as a result the company’s operating profitability has significantly improved. Company had reported robust numbers over FY20-22 |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | |